FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances

Introduction: There is a pressing demand for the development of cancer-specific diagnostic imaging tools, particularly for staging of pancreatic-, gastric- or cholangiocarcinoma, as current diagnostic imaging techniques, including CT, MRI and PET using FDG, are not fully adequate. The novel PET-tracer “FAPI” has the potential to visualize even small tumour deposits employing the tumour-specific expression of fibroblast-activating protein (FAP) in malignant cells. Methods: We performed a systematic review to select studies investigating the use of FAPI PET for staging pancreatic-, gastric- and cholangiocarcinoma (PROSPERO CRD42022329512). Patient-wise and lesion-wise comparisons were performed for primary tumour (T), lymph nodes (N), organ metastases (M) and peritoneal carcinomatosis (PC). Maximum standardized uptake values (SUVmax) and tumour-to-background ratios (TBR) were compared between PET using FAPI versus FDG (if reported). Results: Ten articles met the inclusion criteria. In all studies, FAPI PET showed superiority over FDG-PET/CT/MRI for the detection of T, N, M and PC, both in the patient-wise and in lesion-wise comparisons (when performed). Additionally, higher SUVmax and TBRmax values were reported for use of FAPI compared to FDG. Conclusions: The positive results of this review warrant prospective clinical studies to investigate the accuracy and clinical value of FAPI PET for diagnosing and staging patients with pancreatic-, gastric- and cholangiocarcinoma.

[1]  X. Lan,et al.  68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT , 2021, The Journal of Nuclear Medicine.

[2]  F. Daams,et al.  18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC). , 2021, JAMA surgery.

[3]  Ping Guo,et al.  Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  P. Choyke,et al.  FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? , 2021, Cancers.

[5]  Zan-yi Wu,et al.  Intense [68Ga]Ga-FAPI-04 uptake in solitary fibrous tumor/hemangiopericytoma of the central nervous system , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  G. Lahat,et al.  Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  C. Gündoğan,et al.  68Ga-FAPI Uptake of Thyroiditis in a Patient With Breast Cancer. , 2021, Clinical nuclear medicine.

[8]  Shaobo Yao,et al.  Increased 68Ga-FAPI-04 Uptake in Schmorl Node in a Patient With Gastric Cancer. , 2021, Clinical nuclear medicine.

[9]  Wei Zhang,et al.  Elevated 68Ga-FAPI Activity in Splenic Hemangioma and Pneumonia. , 2021, Clinical nuclear medicine.

[10]  Xiao Yang,et al.  Increased 68Ga-FAPI Uptake in Chronic Cholecystitis and Degenerative Osteophyte. , 2021, Clinical nuclear medicine.

[11]  X. Lan,et al.  Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Hua Wu,et al.  Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  D. Jäger,et al.  Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas , 2020, The Journal of Nuclear Medicine.

[14]  R. Tothill,et al.  FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology? , 2020, The Journal of Nuclear Medicine.

[15]  Hua Wu,et al.  Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. , 2020, Radiology.

[16]  Ping Guo,et al.  Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Haitao Zhao,et al.  Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Hua Wu,et al.  Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Haitao Zhao,et al.  Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[21]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.

[22]  K. Conlon,et al.  The Role of Staging Laparoscopy in Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis , 2018, Digestive Surgery.

[23]  David Moher,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement , 2018, JAMA.

[24]  Spyridon N Papageorgiou,et al.  Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. , 2018, Journal of clinical epidemiology.

[25]  G. Poston,et al.  Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma , 2017, The British journal of surgery.

[26]  Susan Mallett,et al.  Circulating MicroRNAs as a Novel Class of Diagnostic Biomarkers in Gastrointestinal Tumors Detection: A Meta-Analysis Based on 42 Articles , 2014, PloS one.